A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer

被引：0

作者：

Reckamp, Karen L. ^{[1
]}

Akerley, Wallace ^{[2
]}

Edelman, Martin J. ^{[3
]}

Halmos, Balazs ^{[4
]}

He, Kai ^{[5
,6
]}

Johnson, Melissa ^{[7
]}

Mudad, Raja ^{[8
,9
]}

Neal, Joel W. ^{[10
]}

Owonikoko, Taofeek K. ^{[11
]}

Patel, Jyoti D. ^{[12
]}

Patel, Sandip P. ^{[13
]}

Riess, Jonathan W. ^{[14
]}

Sacher, Adrian G. ^{[15
]}

Turcotte, Simon ^{[16
]}

Villaruz, Liza C. ^{[17
]}

Zauderer, Marjorie G. ^{[18
]}

Farsaci, Benedetto ^{[19
]}

Hasan, Aisha ^{[19
]}

Patel, Roma ^{[20
]}

Wu, Yuehui ^{[19
]}

Chisamore, Michael ^{[21
]}

Lam, Vincent ^{[22
]}

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Huntsman Canc Inst, Salt Lake City, UT USA

[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[6] James Canc Hosp, Columbus, OH USA

[7] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA

[9] Sylvester Comprehens Canc Ctr, Miami, FL USA

[10] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Chicago, Chicago, IL 60637 USA

[13] UC San Diego Moores Canc Ctr, San Diego, CA USA

[14] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[17] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[18] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[19] GSK, Philadelphia, PA USA

[20] GSK, Uxbridge, Middx, England

[21] Merck & Co Inc, N Wales, PA USA

[22] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT225

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT225

引用

页数：3

共 34 条

[1] Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
Reckamp, K. L.
Akerley, W.
Calvo, E.
Clarke, J.
Edelman, M. J.
He, K.
Moreno, V.
Neal, J. W.
Owonikoko, T. K.
Patel, J. D.
Patel, S. P.
Riess, J. W.
Sacher, A. G.
Turcotte, S.
Villaruz, L. C.
Zauderer, M. G.
Farsaci, B.
Skoura, N.
Chisamore, M.
Johnson, M. L.
ANNALS OF ONCOLOGY, 2019, 30 : 657 - +
[2] Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
Nishihori, Taiga
Kaufman, Jonathan L.
Hoffman, James E.
Blouch, Kristin
Pandit, Sunil
Butler, Emily
Jain, Amit
Wu, Yuehui
DeYoung, M. Phillip
Hasan, Aisha N.
Rapoport, Aaron P.
BLOOD, 2019, 134
[3] Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
Nishihori, Taiga
Kaufman, Jonathan L.
Hoffrnan, James E.
Blouch, Kristin
Pandit, Sunil
Butler, Emily
Jain, Amit
Wu, Yuehui
DeYoung, M. Phillip
Hasan, Aisha N.
Farsaci, Benedetto
Chisamore, Michael
Rapoport, Aaron P.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S269 - S270
[4] Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma
D'Angelo, Sandra
Demetri, George
Van Tine, Brian
Druta, Mihaela
Glod, John
Chow, Warren
Tress, Jenna
DeYoung, M. Phillip
Hasan, Aisha
Wu, Yuehui
Turner, David
Ji, Ran
Gyurdieva, Alexandra
Araujo, Dejka
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[5] DECITABINE GENE MODULATION SENSITIZES HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) TO NY-ESO-1 TCR IMMUNOTHERAPY LETETRESGENE AUTOLEUCEL; GSK3377794) IN VIVO
Pankov, Dmitry
Eleftheriadou, Ioanna
Domogala, Anna
Brett, Sara
Patasic, Lea
Kijewska, Magdalena
Thripp, Gary
Euesden, Jack
Klapwijk, Jan
Soor, Katrina
Damm, Miriam
Hill, Mark D.
Georgouli, Mirella
Shalabi, Aiman
Britten, Cedrik
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A60 - A61
[6] FINAL ANALYSIS OF THE PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC T-CELL RECEPTOR (TCR) T-CELL THERAPY (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA (SS)
D'Angelo, Sandra
Demetri, George
Van Tine, Brian
Druta, Mihaela
Glod, John
Chow, Warren
Pandya, Naimish
Hasan, Aisha
Chiou, Victoria
Tress, Jenna
Edwards, Julie
Young, Tim
Woessner, Mary
Gyuerdieva, Alexandra
Zajic, Stefan
Goodison, Sophia
Araujo, Dejka
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A182 - A183
[7] Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design
D'Angelo, Sandra
Blay, Jean-Yves
Chow, Warren
Demetri, George
Thistlethwaite, Fiona
Wagner, Michael
Loeb, David
Attia, Steven
Razak, Albiruni
Haanen, John
Hasan, Aisha
Billiard, Julia
Pearce, Laura
Wu, Yuehui
Ji, Ran
Johnson, Laura
Srinath, Chandra
Shalabi, Aiman
Strauss, Sandra
Thornton, Katherine
Mackall, Crystal
Tap, William
Van Tine, Brian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[8] Safety and activity of autologous T cells with enhanced NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and - untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
D'Angelo, Sandra P.
Blay, Jean-Yves
Chow, Warren Allen
Demetri, George D.
Thistlethwaite, Fiona
Sen, Shiraj
Razak, Albiruni Ryan Abdul
Haanen, John B. A. G.
Noujaim, Jonathan Christopher
Johnson, Melissa Lynne
Laetsch, Theodore Willis
Chiou, Victoria L.
Pearce, Laura
Faitg, Thomas H.
Ji, Ran
Johnson, Laura A.
Shalabi, Aiman M.
Thornton, Katherine Anne
Mackall, Crystal
Van Tine, Brian Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] ANALYSIS OF NY-ESO-1 EXPRESSION IN SPECIMENS FROM A PHASE I/II NY-ESO-1 T-CELL THERAPY CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER AND FROM EXPLORATORY STUDIES IN MULTIPLE TUMOR TYPES
Barnes, Bryan
Shan, Ming
Blouch, Kristin
Altan, Mehmet
Kim, Jaegil
Ramos-Hernandez, Natalia
Corigliano, Ellie
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A482 - A482
[10] Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report
Xia, Yan
Tian, Xiaopeng
Wang, Juntao
Qiao, Dongjuan
Liu, Xianhao
Xiao, Liang
Liang, Wenli
Ban, Dongcheng
Chu, Junjun
Yu, Jiaming
Wang, Rongfu
Tian, Geng
Wang, Mingjun
ONCOLOGY LETTERS, 2018, 16 (06) : 6998 - 7007

← 1 2 3 4 →